BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

BioNTech SE Sponsored ADR (NASDAQ:BNTX) has been assigned a consensus rating of “Moderate Buy” from the nineteen analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $129.5625.

Several equities research analysts have commented on the stock. Truist Financial raised shares of BioNTech to a “strong-buy” rating in a research report on Wednesday, March 25th. Canaccord Genuity Group cut their price target on shares of BioNTech from $171.00 to $158.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Citigroup cut their price target on shares of BioNTech from $145.00 to $130.00 and set a “buy” rating on the stock in a research report on Wednesday, March 11th. Sanford C. Bernstein assumed coverage on shares of BioNTech in a research report on Thursday, May 21st. They set a “market perform” rating and a $96.00 price target on the stock. Finally, Wells Fargo & Company cut their price target on shares of BioNTech from $150.00 to $140.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th.

BioNTech Price Performance

Shares of BNTX stock opened at $89.59 on Friday. BioNTech has a 12-month low of $79.52 and a 12-month high of $124.00. The firm has a market capitalization of $22.66 billion, a price-to-earnings ratio of -15.24 and a beta of 1.32. The company has a quick ratio of 8.74, a current ratio of 8.80 and a debt-to-equity ratio of 0.01. The firm has a fifty day moving average of $94.56 and a 200-day moving average of $98.97.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Saturday, February 14th. The company reported ($0.39) earnings per share for the quarter. The company had revenue of $1.06 billion during the quarter. BioNTech had a negative return on equity of 5.30% and a negative net margin of 44.39%. On average, equities research analysts forecast that BioNTech will post -4.71 earnings per share for the current year.

BioNTech announced that its Board of Directors has initiated a share buyback plan on Thursday, May 7th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the company to purchase up to 4.2% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board believes its shares are undervalued.

Insider Activity

In other news, COO Sierk Poetting sold 50,000 shares of the company’s stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $110.56, for a total value of $5,528,000.00. Following the sale, the chief operating officer directly owned 399,387 shares of the company’s stock, valued at approximately $44,156,226.72. This represents a 11.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 19.20% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of BNTX. Royal Bank of Canada raised its holdings in BioNTech by 95.9% in the 1st quarter. Royal Bank of Canada now owns 7,177 shares of the company’s stock valued at $653,000 after acquiring an additional 3,514 shares during the period. NewEdge Advisors LLC bought a new position in BioNTech in the 1st quarter valued at about $167,000. Russell Investments Group Ltd. raised its holdings in BioNTech by 368,800.0% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,067 shares of the company’s stock valued at $1,178,000 after acquiring an additional 11,064 shares during the period. Natixis bought a new position in BioNTech in the 2nd quarter valued at about $985,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in BioNTech by 2.9% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 492,045 shares of the company’s stock valued at $52,416,000 after acquiring an additional 13,788 shares during the period. 15.52% of the stock is owned by institutional investors.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.